Fingolimod Pregnancy and Breastfeeding Warnings
Fingolimod is also known as: Gilenya
Fingolimod Pregnancy Warnings
Fingolimod has been assigned to pregnancy category C by the FDA. Animal studies have revealed evidence of fetal harm, including teratogenicity and embryolethality. There are no controlled data in human pregnancy. The manufacturer recommends that fingolimod should only be used during pregnancy when the potential benefits outweigh the potential risks to the developing fetus. In order to avoid potential fetal harm, women of childbearing potential should avoid pregnancy during and for 2 months after discontinuation of fingolimod.
Developmental toxicity, including teratogenicity and embryolethality has been reported in rats and rabbits following oral administration of fingolimod during organogenesis. In rats, the most frequently reported fetal visceral malformations were persistent truncus arteriosus and ventricular septal defect. Fingolimod affects the receptor (sphingosine 1-phosphate) which is involved in vascular formation during embryogenesis. Additionally, following oral administration of fingolimod in rats during pregnancy and lactation, pup survival was reduced and a neurobehavioral deficit was reported in the offspring. The effects of fingolimod during labor and delivery are unknown. To monitor maternal-fetal outcomes of pregnant women exposed to fingolimod therapy, a pregnancy registry has been established. Physicians are encouraged to prospectively register pregnant patients, or pregnant women may register themselves by calling: 1-877-598-7237.
Fingolimod Breastfeeding Warnings
There are no data on the excretion of fingolimod into human breast milk; however, it is excreted into the milk of lactating rats. The effects in the nursing infant are unknown. The manufacturer recommends that due to the potential for serious adverse reactions in nursing infants, a decision should be made to discontinue nursing or discontinue the drug, taking into account the benefit of breast-feeding to the infant and the importance of the drug to the mother.
- Fingolimod use while Breastfeeding (in more detail)
- fingolimod Consumer Information
- Pregnancy Support Group
- FDA Pregnancy Categories
- Medicine use during Pregnancy
- Medicine use while Breastfeeding
- Safe Medications during Breastfeeding
Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and Drugs.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This drug information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information in contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.